Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.

MLA

Rovers, Koen P., et al. “Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.” JAMA Surgery, vol. 156, no. 8, Aug. 2021, pp. 710–20. EBSCOhost, https://doi.org/10.1001/jamasurg.2021.1642.

APA

Rovers, K. P., Bakkers, C., Nienhuijs, S. W., Burger, J. W. A., Creemers, G.-J. M., Thijs, A. M. J., Brandt-Kerkhof, A. R. M., Madsen, E. V. E., van Meerten, E., Tuynman, J. B., Kusters, M., Versteeg, K. S., Aalbers, A. G. J., Kok, N. F. M., Buffart, T. E., Wiezer, M. J., Boerma, D., Los, M., de Reuver, P. R., … de Hingh, I. H. J. T. (2021). Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial. JAMA Surgery, 156(8), 710–720. https://doi.org/10.1001/jamasurg.2021.1642

Chicago

Rovers, Koen P, Checca Bakkers, Simon W Nienhuijs, Jacobus W A Burger, Geert-Jan M Creemers, Anna M J Thijs, Alexandra R M Brandt-Kerkhof, et al. 2021. “Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.” JAMA Surgery 156 (8): 710–20. doi:10.1001/jamasurg.2021.1642.